Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Stefan Rüdiger (Ulm, Germany), Stefan Rudiger, Cornelia Kropf-Sanchen, Gerlinde Schmidtke-Schrezenmeier, Marta Aksentiy, Katja Hoss, Wolfgang Rottbauer. Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab. Eur Respir J 2016; 48: Suppl. 60, 4845

Member's Comments

No comment yet.

Related content which might interest you: ALK/EML4 translocation in non-squamous NSCLC and their predictors Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Treatment of advanced non-small cell lung cancer with trofosfamide Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Algorithm of preoperative N-staging of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Electrospray-mediated local chemotherapy of lung carcinoma in mice Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Molecular profiling of lung squamous carcinogenesis Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 The prognostic value of D-dimer in lung carcinoma Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Outcomes of radical treatment of early stage non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Improving survival for NSCLC patients in the national lung cancer audit Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Does IASLC/ATS/ERS classification of lung adenocarcinoma impacts prognosis? Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Locoregional recurrence after pulmonary segmentectomy of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013